NFKK 2014

Friday September 19

09:00

Morning Plenary session - Room: F3

Chair: Anne Ricksten

Application of massively parallel sequencing (MPS) for clinical analyses: challenges and opportunities (401)
Ulf Gyllensten, Sweden

09:45

Coffee and exhibition in the exhibition and poster area

10:15

Room: F1

Clinical laboratory education today and tomorrow

The different professions within laboratory medicine complement each other. The education programs are under development and revision. The future laboratory medicine will be dynamic with new biomarkers and techniques. The session will illustrate the situation within the Nordic countries.
Chairs: Mats Ohlson and Camilla Hesse

10:15-10:30 Collaborative Design of Educational Model for Clinical Biochemists in Swedish Laboratory Medicine –“The Swedish Model” (402)
Tom M Pettersson, Sweden

10:30-10:40 Training of Clinical Biochemists in Finland (403)
Päivi Laitinen, Finland

10:40-10:55 Biomedical laboratory science, present and future aspects on the education (404)
Camilla Hesse, Sweden

10:55-11:05 Clinical laboratory education today and tomorrow – the Swedish physician's perspective (405)
Christian Löwbeer,Sweden

11:05-11:20 Specialist training in the Nordic Countries and the Danish model (406)
Nete Hornung,Denmark

11:20-11:30 Panel discussion

Room: F2

Future use of cancer biomarkers

Our knowledge of how cancer develops and evolves into stable tissue has recently been rewritten. In addition, several cancer biomarkers are now used for screening and to guide personalised treatment. This session will give an overview of our new vistas in cancer biology and provide examples of future cancer biomarkers that will aid in the diagnosis and treatment of cancer

Chairs: Julia Asp and Anne Ricksten

10:15 - 10:45 Do you think (cancer) medicine is modern? The need for a new cancerparadigm (407)
Ingemar Ernberg,Sweden

10:45 - 11:15 Combines assessment of six Tumor Markers for the Diagnosis and Histological Diagnosis of Lung Cancer (408)
Rafael Molina,Spain

11:15 - 11:45 Biomarkers increase survival in ovarian cancer (409)
Karin Sundfeldt, Sweden

11:45- 12:00 Elevated plasma Cobalamin Predicts a Poor Survival for Cancer Patients – a Population-based Cohort Study (410)
Johan Frederik Berg Arendt, Denmark

Room: F3

Biomarkers of kidney disease

How to estimate kidney function has been debated under decades. Recently novel kidney function biomarkers have been found, ways to standardise measurement of cystatin C have been presented and new better formulas for both creatinine- and cystatin C-based estimations of GFR have been developed. This sessionwill discuss how kidney function should be measured. In addition, novel methods for measurement of carbohydrate urin markers and how cardiac markers might be affected by kidney function will be discussed.
Chairs: Ola Hammarsten and Anders Larson

10:15 - 10:45 Biomarkers of Kidney Disease (411)
Anders Grubb, Sweden

10:45 - 11:15 Simple protocol for preparation and nLC-MS/MS characterization of proteoglycan linkage region glycopeptides of human plasma, urine and cerebrospinal fluid samples (412)
Göran Larson, Sweden

11:15 - 11:25 Cystatin C-based GFR is more closely associated with mortality than creatinine-based GFR in unselected patients seeking health care (413)
Johanna Helmersson-Karlqvist, Sweden

11:25 - 11:35 Troponin I levels are less dependent on glomerular filtration rate compared to Troponin T and other cardiac biomarkers (414)
Christian Bjurman, Sweden

12:00

Poster Prizewinningceremony and Closing Remarks - Room: F3

Kongress.se